-
Featured
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
Noopur Raje, MD, of the Massachusetts General Hospital Cancer Center, and colleagues determined in a phase 1 trial that idecabtagene vicleucel had promising antitumor activity in a heavily pretreated population of patients with multiple myeloma, and most nonhematologic toxic effects were grade 1 or 2.
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
Bob S. Carter, MD, PhD, is the chief of the Department of Neurosurgery at Massachusetts General Hospital. In this Q&A, Dr. Carter elaborates on intraoperative molecular diagnostics. Dr. Carter is also a 2021 Congress of Neurological Surgeons (CNS) honored guest.
-
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
Massachusetts General Hospital researchers observed low rates of acute kidney injury (AKI) after tisagenlecleucel therapy but detected the first case of AKI in a patient with macrophage activation syndrome/hemophagocytic lymphohistiocytosis triggered by the therapy.
-
Phase 1 Trial Supports Safety and Efficacy of Novel CAR-T Therapy for Large B-cell Lymphomas
Lisocabtagene maraleucel, an investigational CAR T-cell product, was linked to low incidence of cytokine release syndrome and neurological events in a phase 1 seamless design pivotal trial and often led to rapid and durable remission among patients with high-risk relapsed/refractory large B-cell lymphoma.
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
CAR T-cell Therapy Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
-
Daniel B. Rubin, MD, PhD
Neurologist
Recent Article
New Tool Identifies Risk of Neurotoxicity After CAR T-cell Therapy
-
Jeremy Slade Abramson, MD
Director, Jon and JoAnn Hagler Center for Lymphoma, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Phase 1 Trial Supports Safety and Efficacy of Novel CAR-T Therapy for Large B-cell Lymphomas
-
Meghan E. Sise, MD
Nephrologist, Massachusetts General Hospital, Associate Professor of Medicine
Recent Article
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
-
Noopur S. Raje, MD
Director of the Multiple Myeloma Center, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Immunotherapies to Treat Glioblastoma
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
